Rua Bioscience (RUA) H2 2025 earnings summary

Executive summary

• FY25 revenue increased to $1.90m, up from $0.32m in FY24, reflecting strong commercial momentum.

• Significant reduction in loss before tax to $3.46m in FY25 from $13.72m in FY24.

• Revenue from customers reached $1.51m, up from $86K year-over-year.

• Commercial milestones achieved with revenue generation in five key international markets.

Financial highlights

• FY25 revenue rose to $1.90m, a nearly sixfold increase year-over-year.

• Loss before tax significantly reduced to $3.46m from $13.72m in the prior year.

• $1.5m received from shareholders during the financial year.

Outlook and guidance

• Sales momentum expected to continue into FY26, with anticipated revenue growth from both established and emerging markets.

• Focus remains on accelerating commercial performance and strengthening international partnerships.